Antares Stock Hits New 52-Week High (ATRS)

NEW YORK ( TheStreet) -- Antares Pharma (Nasdaq: ATRS) hit a new 52-week high Tuesday as it is currently trading at $3.84, above its previous 52-week high of $3.75 with 325,626 shares traded as of 9:40 a.m. ET. Average volume has been one million shares over the past 30 days.

Antares has a market cap of $369.1 million and is part of the health care sector and health services industry. Shares are up 60.9% year to date as of the close of trading on Monday.

Antares Pharma Inc., a pharmaceutical company, engages in the development and marketing of self-injection pharmaceutical products and technologies, and topical gel-based products.

TheStreet Ratings rates Antares as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. You can view the full Antares Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

Teva Discusses EpiPen Comps as Host of Generics Unveiled

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Insider Trading Alert - FLML, WLFC And ATRS Traded By Insiders

Antares Pharma (ATRS) Stock Lower on Q4 Results